# Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

> **NCT04707547** · PHASE4 · COMPLETED · sponsor: **Taipei Medical University WanFang Hospital** · enrollment: 5 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** immunotherapy with Nivolumab
- **PROCEDURE:** Radiofrequency Ablation

## Key facts

- **NCT ID:** NCT04707547
- **Lead sponsor:** Taipei Medical University WanFang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-16
- **Primary completion:** 2020-07-23
- **Final completion:** 2020-07-23
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707547, "Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04707547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*